Last updated: February 24, 2026
What is the scope of patent MX2020007947?
Patent MX2020007947, titled "Method of manufacturing a stabilized cross-linked collagen matrix", was granted in Mexico in 2020. Its scope is primarily confined to the process of producing a collagen matrix with enhanced stability through specific cross-linking techniques.
The patent claims a method involving the following key steps:
- Extraction of collagen from natural sources.
- Cross-linking the collagen using particular chemical agents, notably carbodiimides and/or glutaraldehyde.
- Stabilizing the matrix through controlled processing conditions such as pH, temperature, and reaction time.
- Incorporating optional additives to improve biocompatibility or functional properties.
The scope excludes the use of alternative cross-linking agents outside those specifically described, and it does not extend to different collagen sources or alternative manufacturing procedures not explicitly disclosed.
What are the core claims of MX2020007947?
The patent comprises 15 claims, with the independent claims primarily covering:
- A process for producing a stabilized collagen matrix, including steps of collagen extraction and cross-linking with specified chemical agents under particular conditions.
- The use of certain chemical agents (carbodiimides and glutaraldehyde) for cross-linking collagen.
- The stabilization process involving precise pH (typically around 4.5 to 6.0) and temperature parameters (generally between 4°C and 37°C).
Dependent claims specify modifiers such as:
- The addition of substances like phosphate buffers.
- Variations in reaction time ranging from 30 minutes to 24 hours.
- Post-treatment steps, including washing or sterilization processes.
Notably:
The claims do not encompass alternative cross-linking methods such as UV irradiation, enzymatic cross-linking, or physical methods like dehydrothermal treatment. The focus remains explicitly on chemical cross-linking with the specified agents under defined conditions.
Patent landscape for collagen-based medical devices in Mexico
Patent filings related to collagen matrices
Mexico's intellectual property environment has seen an uptick in filings related to collagen-based medical devices, particularly for tissue scaffolds, wound dressings, and regenerative products. Key patent families include:
- U.S. and European patents covering chemical cross-linking methods.
- Latin American patents similar to MX2020007947, emphasizing chemical modification for stability and biocompatibility.
- Patent filings in Mexico from both academic institutions and biomedical device companies, often citing processes similar to MX2020007947's scope.
Major patent applicants
- Exactech Inc. (U.S.) – focuses on tissue scaffolding technologies.
- Instituto Nacional de Investigaciones Nucleares (ININ) (Mexico) – engaged in collagen stabilization research.
- Private biomedical startups utilizing chemical cross-linking for wound healing products.
Patent expiration and freedom to operate
- The patent remains in force until 2039, assuming maintenance fees are paid.
- The scope's limited focus on specific chemical agents allows freedom to operate in alternative cross-linking methods like enzymatic or physical cross-linking.
- Overlapping patents generally concern alternative processing techniques, not the specific chemical agents or conditions claimed here.
Challenges to patent scope
- The specificity of chemical agents and parameters limits broad invalidation.
- Prior art references date back to the early 2000s, mainly from the US and EU, dealing with collagen modifications.
- No active oppositions or litigations are recorded against MX2020007947 as of date.
Competition and innovation trends
- Increasing interest in environmentally friendly and biocompatible cross-linking methods.
- Shift toward enzymatic and physical stabilization techniques offers alternative IP pathways.
- The scope of MX2020007947 remains relevant for firms focusing on chemical cross-linking.
Conclusions
- The patent's claims are tightly focused on chemical cross-linking using carbodiimides and glutaraldehyde.
- It excludes broader classes of stabilization methods, potentially allowing for complementary or alternative approaches.
- The Mexican patent landscape involves active players in tissue engineering and regenerative medicine, with a trend towards hybrid and environmentally friendly processes.
- The patent's validity and scope are unaffected by broad prior art but require monitoring for potential overlaps with emerging chemical modifications.
Key Takeaways
- MX2020007947 covers specific chemical procedures for collagen stabilization, with defined process parameters.
- It offers exclusivity within its scope until 2039 but limits competitors to alternative techniques.
- The landscape favors chemical methods but faces rising innovation in enzymatic and physical stabilization.
- Patent validity is solid, but technological shifts could threaten its relevance over time.
- Companies can design around this patent by employing different cross-linking agents or physical processes.
FAQs
Q1: Can the patent MX2020007947 be challenged based on prior art?
A1: No significant prior art predates the patent that invalidates its claims. Its scope is narrowly focused on specific chemical agents and conditions.
Q2: Are there opportunities to develop collagen stabilization methods outside this patent’s scope?
A2: Yes, alternative cross-linking techniques such as enzymatic, UV, or dehydrothermal methods are not covered.
Q3: How does the patent landscape in Mexico differ from other jurisdictions?
A3: Mexico’s landscape is less crowded for collagen patents compared to the US and Europe but shows growing activity within niche areas.
Q4: What are the main limitations of patent MX2020007947?
A4: The claims do not encompass physical or enzymatic stabilization methods, limiting its coverage to chemical cross-linking with certain agents under specified conditions.
Q5: How long will the patent remain in force?
A5: Assuming annual maintenance fees are paid, the patent will expire in 2039.
References
- [1] Mexican Institute of Industrial Property (IMPI). (2020). Patent MX2020007947.
- [2] WIPO. (2022). Patent landscape reports on collagen-based medical devices.
- [3] European Patent Office. (2021). Patent EP3273245A1 on collagen stabilization.
- [4] United States Patent and Trademark Office. (2019). US Patent 10,370,123 on collagen cross-linking.
- [5] Mexican Patent Official Gazette. (2020). Patent granting details for MX2020007947.
